BRISTOL-MYERS SQUIBB’s PRAVACHOL (PRAVASTATIN) RECOMMENDED FOR APPROVAL BY FDA ADVISORY COMMITTEE; PANEL SUGGESTS PHASE IV STUDIES IN SPECIAL POPULATIONS